CTLA4 and neoplasm: In agreement with our present work, these emerging studies suggest that TAMs may adapt to a variety of tumor microenvironmental clues during tumor development, by acquiring a large spectrum of states.32 Importantly, recent studies have shown that the use of immune checkpoint inhibitors such as anti‐PD‐1 and anti‐CTLA‐4 can modify the myeloid high‐dimensional landscape in mouse models,33, 34 providing new insights into its mechanisms of action and its clinical applications.